Literature DB >> 7957361

Antiphospholipid antibodies in paediatrics.

A Ravelli1, A Martini, G R Burgio.   

Abstract

Antiphospholipid antibodies, i.e. circulating auto-antibodies to negatively charged phospholipids, are mainly observed in patients with systemic lupus erythematosus, but may also occur in individuals who lack evidence of a well-defined systemic disease. Several studies have suggested that they may play a direct role in the pathogenesis of recurrent vascular thrombosis, repeated abortions, and thrombocytopenia (so-called antiphospholipid antibody syndrome), although the mechanism by which this occurs is still poorly understood. The management of patients with antiphospholipid antibody-related thrombosis includes anti-aggregants, anticoagulants, corticosteroids, and cytotoxic drugs, but the optimum treatment is still controversial. Here we review the test systems used to detect antiphospholipid antibodies and their significance in paediatrics.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7957361     DOI: 10.1007/BF01956999

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  58 in total

Review 1.  The antiphospholipid syndrome: a syndrome in evolution.

Authors:  R A Asherson; R Cervera
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

2.  Stroke in an early adolescent with systemic lupus erythematosus and coexistent antiphospholipid antibodies.

Authors:  D D Dungan; M S Jay
Journal:  Pediatrics       Date:  1992-07       Impact factor: 7.124

3.  Systemic lupus erythematosus and the antiphospholipid syndrome: reflections about the relevance of ARA criteria.

Authors:  J C Piette; B Wechsler; C Francis; P Godeau
Journal:  J Rheumatol       Date:  1992-12       Impact factor: 4.666

4.  Childhood adrenal insufficiency, chorea, and antiphospholipid antibodies.

Authors:  C D Rose; D P Goldsmith
Journal:  Ann Rheum Dis       Date:  1990-06       Impact factor: 19.103

5.  Vasculopathy in the antiphospholipid syndrome: thrombosis or vasculitis, or both?

Authors:  J T Lie
Journal:  J Rheumatol       Date:  1989-06       Impact factor: 4.666

Review 6.  Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance.

Authors:  P E Love; S A Santoro
Journal:  Ann Intern Med       Date:  1990-05-01       Impact factor: 25.391

7.  Syndrome of the black swan.

Authors:  E N Harris
Journal:  Br J Rheumatol       Date:  1987-10

8.  Anticardiolipin antibodies in autoimmune thrombocytopenic purpura.

Authors:  E N Harris; A E Gharavi; U Hegde; G Derue; S H Morgan; H Englert; J K Chan; R A Asherson; G R Hughes
Journal:  Br J Haematol       Date:  1985-02       Impact factor: 6.998

9.  Anticardiolipin antibody, recurrent thrombosis, and warfarin withdrawal.

Authors:  R A Asherson; J K Chan; E N Harris; A E Gharavi; G R Hughes
Journal:  Ann Rheum Dis       Date:  1985-12       Impact factor: 19.103

10.  [Systemic lupus erythematosus manifested by thrombophlebitis of the lower limbs].

Authors:  D Olive; E André; O Brocard; P Labrude; P Alexandre
Journal:  Arch Fr Pediatr       Date:  1979 Sep-Oct
View more
  3 in total

1.  Antiphospholipid antibodies in a child: an unusual presentation without thrombotic events.

Authors:  L Felici; M Santoni; I Carloni; G V Coppa
Journal:  Eur J Pediatr       Date:  1996-11       Impact factor: 3.183

2.  Antiphospholipid syndrome in young patients. Two cases of cerebral ischaemic accidents.

Authors:  G D Di Nucci; G Mariani; P Arcieri; R Cerbo; L Tarani; L Bruni; M C Tozzi; P Vignetti
Journal:  Eur J Pediatr       Date:  1995-04       Impact factor: 3.183

3.  Central retinal vein occlusion in a pediatric patient with SLE and antiphospholipid antibodies without anti-cardiolipin or anti-β2 glycoprotein I antibodies.

Authors:  Seigo Korematsu; Hironori Goto; Chika Gotoh; Ryoko Ohki; Toshiaki Kubota; Tatsuro Izumi
Journal:  BMC Pediatr       Date:  2014-05-03       Impact factor: 2.125

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.